» Articles » PMID: 28275093

Immune Protection Against Reinfection with Nonprimate Hepacivirus

Abstract

Hepatitis C virus (HCV) displays a restricted host species tropism and only humans and chimpanzees are susceptible to infection. A robust immunocompetent animal model is still lacking, hampering mechanistic analysis of virus pathogenesis, immune control, and prophylactic vaccine development. The closest homolog of HCV is the equine nonprimate hepacivirus (NPHV), which shares similar features with HCV and thus represents an animal model to study hepacivirus infections in their natural hosts. We aimed to dissect equine immune responses after experimental NPHV infection and conducted challenge experiments to investigate immune protection against secondary NPHV infections. Horses were i.v. injected with NPHV containing plasma. Flow cytometric analysis was used to monitor immune cell frequencies and activation status. All infected horses became viremic after 1 or 2 wk and viremia could be detected in two horses for several weeks followed by a delayed seroconversion and viral clearance. Histopathological examinations of liver biopsies revealed mild, periportally accentuated infiltrations of lymphocytes, macrophages, and plasma cells with some horses displaying subclinical signs of hepatitis. Following viral challenge, an activation of equine immune responses was observed. Importantly, after a primary NPHV infection, horses were protected against rechallenge with the homologous as well as a distinct isolate with only minute amounts of circulating virus being detectable.

Citing Articles

First National Prevalence in Italian Horse Population and Phylogenesis Highlight a Fourth Sub-Type Candidate of Equine Hepacivirus.

Nardini R, Pacchiarotti G, Svicher V, Salpini R, Bellocchi M, Conti R Viruses. 2024; 16(4).

PMID: 38675957 PMC: 11054338. DOI: 10.3390/v16040616.


Mouse Liver-Expressed Shiftless Is an Evolutionarily Conserved Antiviral Effector Restricting Human and Murine Hepaciviruses.

Zhang Y, Kinast V, Sheldon J, Frericks N, Todt D, Zimmer M Microbiol Spectr. 2023; 11(4):e0128423.

PMID: 37341610 PMC: 10433982. DOI: 10.1128/spectrum.01284-23.


European College of Equine Internal Medicine consensus statement on equine flaviviridae infections in Europe.

Cavalleri J, Korbacska-Kutasi O, Leblond A, Paillot R, Pusterla N, Steinmann E J Vet Intern Med. 2022; 36(6):1858-1871.

PMID: 36367340 PMC: 9708432. DOI: 10.1111/jvim.16581.


Equine Hepacivirus: A Systematic Review and a Meta-Analysis of Serological and Biomolecular Prevalence and a Phylogenetic Update.

Pacchiarotti G, Nardini R, Scicluna M Animals (Basel). 2022; 12(19).

PMID: 36230228 PMC: 9558973. DOI: 10.3390/ani12192486.


Dose-Dependent Hepacivirus Infection Reveals Linkage between Infectious Dose and Immune Response.

Gomer A, Delarocque J, Puff C, Nocke M, Reinecke B, Baumgartner W Microbiol Spectr. 2022; 10(5):e0168622.

PMID: 35993785 PMC: 9602444. DOI: 10.1128/spectrum.01686-22.


References
1.
Shi M, Lin X, Vasilakis N, Tian J, Li C, Chen L . Divergent Viruses Discovered in Arthropods and Vertebrates Revise the Evolutionary History of the Flaviviridae and Related Viruses. J Virol. 2015; 90(2):659-69. PMC: 4702705. DOI: 10.1128/JVI.02036-15. View

2.
Hartlage A, Cullen J, Kapoor A . The Strange, Expanding World of Animal Hepaciviruses. Annu Rev Virol. 2016; 3(1):53-75. PMC: 5523456. DOI: 10.1146/annurev-virology-100114-055104. View

3.
Houghton M, Abrignani S . Prospects for a vaccine against the hepatitis C virus. Nature. 2005; 436(7053):961-6. DOI: 10.1038/nature04081. View

4.
Simmonds P . Genetic diversity and evolution of hepatitis C virus--15 years on. J Gen Virol. 2004; 85(Pt 11):3173-3188. DOI: 10.1099/vir.0.80401-0. View

5.
Drexler J, Corman V, Muller M, Lukashev A, Gmyl A, Coutard B . Evidence for novel hepaciviruses in rodents. PLoS Pathog. 2013; 9(6):e1003438. PMC: 3688547. DOI: 10.1371/journal.ppat.1003438. View